Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
Inhibikase Therapeutics (Nasdaq: IKT) has appointed David McIntyre as Chief Financial Officer, effective April 14, 2025. McIntyre brings over two decades of executive experience in the life sciences sector, having served in C-suite positions at companies including Anthos Therapeutics, HeartWare International, AVITA Medical, Tessa Therapeutics, and Braeburn.
Prior to joining IKT, McIntyre was a Partner at Apple Tree Partners, a multi-billion-dollar life sciences venture capital fund. His background includes roles as a senior attorney at Baker McKenzie and KPMG, focusing on M&A, IPOs, and corporate law. He holds degrees from the University of Sydney, University of Technology Sydney, and an MBA from Duke University's Fuqua School of Business.
Inhibikase Therapeutics (Nasdaq: IKT) ha nominato David McIntyre come Chief Financial Officer, con effetto dal 14 aprile 2025. McIntyre porta con sé oltre due decenni di esperienza esecutiva nel settore delle scienze della vita, avendo ricoperto ruoli di vertice in aziende come Anthos Therapeutics, HeartWare International, AVITA Medical, Tessa Therapeutics e Braeburn.
Prima di unirsi a IKT, McIntyre è stato Partner presso Apple Tree Partners, un fondo di venture capital nel settore delle scienze della vita da miliardi di dollari. Il suo background include ruoli come avvocato senior presso Baker McKenzie e KPMG, concentrandosi su fusioni e acquisizioni, IPO e diritto societario. Ha conseguito lauree presso l'Università di Sydney, l'Università di Tecnologia di Sydney e un MBA presso la Fuqua School of Business della Duke University.
Inhibikase Therapeutics (Nasdaq: IKT) ha nombrado a David McIntyre como Director Financiero, con efecto a partir del 14 de abril de 2025. McIntyre aporta más de dos décadas de experiencia ejecutiva en el sector de las ciencias de la vida, habiendo ocupado puestos en la alta dirección en empresas como Anthos Therapeutics, HeartWare International, AVITA Medical, Tessa Therapeutics y Braeburn.
Antes de unirse a IKT, McIntyre fue Socio en Apple Tree Partners, un fondo de capital de riesgo en ciencias de la vida de varios miles de millones de dólares. Su experiencia incluye roles como abogado senior en Baker McKenzie y KPMG, centrándose en fusiones y adquisiciones, OPI y derecho corporativo. Tiene títulos de la Universidad de Sydney, de la Universidad de Tecnología de Sydney y un MBA de la Escuela de Negocios Fuqua de la Universidad de Duke.
Inhibikase Therapeutics (Nasdaq: IKT)는 David McIntyre를 최고 재무 책임자로 임명하며, 2025년 4월 14일부터 발효됩니다. McIntyre는 Anthos Therapeutics, HeartWare International, AVITA Medical, Tessa Therapeutics 및 Braeburn와 같은 회사에서 C-suite 직책을 맡으며 생명 과학 분야에서 20년 이상의 경영 경험을 보유하고 있습니다.
IKT에 합류하기 전에 McIntyre는 수십억 달러 규모의 생명 과학 벤처 캐피탈 펀드인 Apple Tree Partners의 파트너였습니다. 그의 경력에는 Baker McKenzie 및 KPMG에서 M&A, IPO 및 기업 법률에 중점을 둔 수석 변호사로서의 역할이 포함됩니다. 그는 시드니 대학교, 시드니 기술 대학교에서 학위를 취득했으며, 듀크 대학교 후쿠아 비즈니스 스쿨에서 MBA를 취득했습니다.
Inhibikase Therapeutics (Nasdaq: IKT) a nommé David McIntyre au poste de directeur financier, à compter du 14 avril 2025. McIntyre apporte plus de vingt ans d'expérience exécutive dans le secteur des sciences de la vie, ayant occupé des postes de direction dans des entreprises telles qu'Anthos Therapeutics, HeartWare International, AVITA Medical, Tessa Therapeutics et Braeburn.
Avant de rejoindre IKT, McIntyre était associé chez Apple Tree Partners, un fonds de capital-risque dans le domaine des sciences de la vie de plusieurs milliards de dollars. Son parcours comprend des rôles en tant qu'avocat senior chez Baker McKenzie et KPMG, se concentrant sur les fusions et acquisitions, les introductions en bourse et le droit des sociétés. Il est titulaire de diplômes de l'Université de Sydney, de l'Université de Technologie de Sydney et d'un MBA de la Fuqua School of Business de l'Université Duke.
Inhibikase Therapeutics (Nasdaq: IKT) hat David McIntyre zum Chief Financial Officer ernannt, der am 14. April 2025 in Kraft tritt. McIntyre bringt über zwei Jahrzehnte an Führungserfahrung im Bereich der Lebenswissenschaften mit und hat in C-Suite-Positionen bei Unternehmen wie Anthos Therapeutics, HeartWare International, AVITA Medical, Tessa Therapeutics und Braeburn gedient.
Vor seinem Eintritt bei IKT war McIntyre Partner bei Apple Tree Partners, einem Milliarden-Dollar-Venture-Capital-Fonds für Lebenswissenschaften. Sein Hintergrund umfasst Positionen als leitender Anwalt bei Baker McKenzie und KPMG, mit Schwerpunkt auf M&A, IPOs und Unternehmensrecht. Er hat Abschlüsse von der University of Sydney, der University of Technology Sydney und einen MBA von der Fuqua School of Business der Duke University.
- Appointment of experienced CFO with over 20 years of executive experience in life sciences
- New CFO brings strong background in financial strategy and capital markets
- Addition of executive with extensive M&A and IPO experience
- None.
BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“PAH”), today announced the appointment of David McIntyre as Chief Financial Officer, effective April 14, 2025.
“David has extensive experience in financial strategy and corporate governance, as well as an established reputation within the life sciences capital markets sector, and we are thrilled to welcome him as our new Chief Financial Officer,” said Mark Iwicki, Chief Executive Officer of Inhibikase Therapeutics. “We look forward to leveraging his expertise as we continue to advance IkT-001 for PAH patients.”
Mr. McIntyre has over two decades of executive experience in the life sciences sector, having held numerous C-suite level roles at both public and private biotech and medical device companies, including Anthos Therapeutics, Inc., HeartWare® International, Inc., AVITA Medical, Inc., Tessa Therapeutics, Inc., and Braeburn, Inc. In addition to his executive leadership roles, Mr. McIntyre spent nearly a decade as a Partner at Apple Tree Partners, a multi-billion-dollar life sciences venture capital and growth equity fund. Prior to entering the life sciences industry, he practiced as a senior attorney at Baker McKenzie and KPMG, specializing in mergers and acquisitions, initial public offerings, and corporate law. He also held senior finance positions at multinational corporations and high-growth companies, including Rio Tinto.
Mr. McIntyre holds a Bachelor of Economics (Accounting) from the University of Sydney, a Bachelor of Laws from the University of Technology, Sydney, and a Master of Business Administration from Duke University’s Fuqua School of Business, where he was recognized as a Fuqua Scholar. He is also a Certified Practicing Accountant and is admitted as a legal practitioner of the Supreme Court of New South Wales and the High Court of Australia.
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing Abelson Tyrosine Kinase inhibitor therapeutics for Cardiopulmonary disease. Inhibikase’s cardiopulmonary disease portfolio is led by IkT-001, a prodrug of imatinib mesylate, for PAH. Inhibikase is headquartered in Atlanta, Georgia with offices in Lexington, Massachusetts.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the initiation of the Company’s continued progression of IkT-001 in PAH, the Company’s future activities, or future events or conditions; and expectations regarding the anticipated contribution of Mr. McIntyre to our operations and progress. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to commence and execute a Phase 2b ‘702’ trial to evaluate IkT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contacts:
Investor Relations:
Michael Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
FAQ
When does David McIntyre start as CFO of Inhibikase Therapeutics (IKT)?
What is David McIntyre's professional background before joining IKT?
What is Inhibikase Therapeutics' (IKT) main focus area?
What is IKT's lead product candidate mentioned in the announcement?
